Neutralizing Interferon Type 1 in Hidradenitis Suppurativa

Inclusion Criteria

• •Men and women aged over 18
• •Patients with Hidradenitis suppurativa (Hurley stages II-III)
• •Disease affecting at least two distinct anatomical areas,
• •Total count of abscesses (A) and inflammatory nodules (N) ≥ 3
• •IHS4 score ≥ 11
• •Treatment of pain with opioids (≥ 20 mg/day)
• •Resistance to previous use (for at least 3 months) of systemic antibiotics and TNF inhibitors (infliximab or adalimumab) or anti-IL17 (secukinumab).
• •Vaccinations against SARS-CoV-2 and influenza up to date (or able to be carried out prior to the study procedure)
• •Women using an effective method of contraception
• •Signed informed consent